Second Generation Cell and Gene-based Therapies: Biological Advances, Clinical Outcomes and Strategies for Capitalization

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalization serves as the only volume to the market to bridge basic science, clinical therapy, technology development and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths which will ultimately facilitate clinical delivery of cutting edge curative products. The next waves of innovation are reviewed in depth for hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as for enabling technologies such as gene and genome editing. Additionally, deep dives in product fundamentals, history of science, pathobiology of diseases, scientific and technological bases, and financing and technology adoption constraints are taken in order to unravel what will shape the cytotherapy industry to the horizon 2025 and beyond. The outcome is not simply a scientific book, but a global perspective on the nascent field combining science, business, and strategic fundamentals. Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalizationPerspectives section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted and combines scientific and business insightsEdited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies INDICE: PART I: SCIENCE 1. Riding the technology S-curves in cytotherapies 2. Gene therapy 3. Therapeutic potential of cells of the immune system 4. T-cell engineering 5. Engineered hematopoietic stem cells 6. Second generation MSCs 7. First generation induced Pluripotent Stem Cells 8. Editing technologies for the mammalian genomes 9. The Next Wave:  Tissue Replacement and Organ Replacement PART II: TRANSLATION 10. Gene Therapy clinical trials 11. CAR T-cells clinical trials 12. Cytotherapy clinical trials in genetic disorders of the blood 13. Late stage Clinical trials data from minimally manipulated MSCs and translational advances with genetically engineered MSCs PART III: THE NEXT FRONTIER 14. Second generation genome editing technologies in drug discovery 15. Harnessing the therapeutic potential of dendritic cells 16: Second generation CAR T-cells 17. Capitalising on the potential of neural stem cells in oncology and CNS 18. Combinatory cytotherapy PART IV: PERSPECTIVES 19.  Cytotherapy manufacturing: service-based business model vs. off-the-shelf blockbuster business model 20: Second generation cytotherapy business models: the case of CAR-T cells business sustainability 21. Financing the new wave of transformational oncology treatments 22. Strategic alliances in cytotherapies and gene therapies. Funding the new wave of cell therapeutics 23. Solid tumor immune-oncology

• ISBN: 978-0-12-812034-7
• Editorial: Academic Press
• Encuadernacion: Cartoné
• Páginas: 500
• Fecha Publicación: 01/11/2018
• Nº Volúmenes: 1
• Idioma: Inglés